FIELD: pharmacology.
SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabetes.
EFFECT: application of these inventions allows to provide a basal insulin reserve within 24 hours after a subcutaneous injection of a single dose.
16 cl, 9 dwg, 12 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF LONG-ACTING INSULIN | 2011 |
|
RU2564104C2 |
| TREATING DIABETES MELLITUS WITH LONG-ACTING INSULIN FORMULATIONS | 2014 |
|
RU2705797C2 |
| COMBINATION OF INSULIN AND GLP-1 AGONIST | 2014 |
|
RU2682671C2 |
| COMBINATION OF INSULIN AND GLP-1 AGONIST | 2009 |
|
RU2532378C2 |
| TREATING DIABETES MELLITUS BY INSULIN INJECTIONS AS LITTLE AS ONCE DAY | 2009 |
|
RU2540922C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AGONIST GLP-1, INSULIN AND METHIONINE | 2010 |
|
RU2537239C2 |
| STABLE COMPOSITION OF INSULIN GLULISIN | 2014 |
|
RU2691059C2 |
| INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION | 2014 |
|
RU2684398C2 |
| PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2670106C2 |
| APPLICATION OF SUPERFAST-ACTING INSULIN | 2009 |
|
RU2519706C2 |
